Absci dans l'actualité
Création de médicaments basée sur l'IA
Tamtam a trouvé 20 articles récents sur Absci.
- Is Absci (ABSI) A Bargain On Its ABS 201 Phase 2 Trial Update?
- Absci (NASDAQ:ABSI) Shares Down 5.5% - Here's Why
- Absci Corporation (NASDAQ:ABSI) Stock Has Average Target Price of $13.71
- Phase 2 Trial Plans Could Be A Game Changer For Absci Stock (ABSI)
- Weekly Recap: ABS-201 Phase 2 STORYLINE and Needham $11 Buy
- Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027
- Absci (NASDAQ:ABSI) Stock Jumps 6.1% - Still a Buy?
- Guggenheim reiterates Absci stock rating on endometriosis trial delay
- Absci Corporation $ABSI Shares Newly Acquired by Bank of America Corp DE
- Absci Stock In Focus As Phase 2 Trial Plan Takes Shape
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- Absci (ABSI) Maps Out Phase 2 Trial, Is It Still 29% Undervalued?
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- Endometriosis affects roughly 1 in 10 women of reproductive age. Absci plans a drug trial in about 150 patients.
- Absci Corporation Announces Preliminary Details for Phase 2 Storyline? Trial of Ai-Designed Antibody Abs-201? for Endometriosis
- Absci (NASDAQ:ABSI) Stock Price Down 8.3% - What's Next?
- Absci (NASDAQ:ABSI) Earns "Buy" Rating from Needham & Company LLC
- Needham reiterates Buy rating on Absci, $11 price target
- Absci (ABSI) Stock Looks Expensive Against Its Book Value
- Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Absci ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires